ANKMJ

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Index
Original Article
Investigation of brucellosis cases in and around Yozgat Province
Aims: Brucellosis causes a zoonotic infectious disease that is very common in our country as well as around the whole world. Infected individuals most frequently present with nonspecific symptoms such as fever, chills, malaise, and generalized body pain. Therefore, it is very difficult to diagnose. When diagnosis and treatment are delayed, it causes serious complications. It can cause pictures with high mortality, such as epididymoorchitis, endocarditis, hepatitis, neurobrucellosis, and pancytopenia. The first approach to treatment is rest. Antibiotics with intracellular bactericidal action should be used in combination due to resistance development.
Methods: 136 individuals with serum titers who were diagnosed with brucellosis by serological tests and who applied to our hospital between 2017-2022 were included in the study. The patient files were analyzed to evaluate the complaints of these individuals, their Brucella ELISA titers, serum aspartate aminotransferase (AST), alanine aminotranspherase (ALT), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH) values, if any, at the time of diagnosis, the treatments they received, and the response to the treatment.
Results: The first complaints of 136 patients who were diagnosed with brucellosis by serological tests were the most common; Joint pain was present in 48 (35.29%), widespread body pain in 26 (19.11%), and fever in 18 (13.23%). Sacroiliitis in 5 (3.67%), gonarthrosis in 4 (2.94%), bursitis in 4 (2.94%), discitis in 3 (2.2), and psoriasis in 1 of the patients’ abscess (0.73%) was detected. R=0.28 in the same direction between the first titers recognized by the patients and ALT; the same direction between titer and LDH R=0.30; the same ratio between titer and CRP is R=0.45; and there is a correlation coefficient of R=0.26 between titer and sediment in the same direction. It is important to take these correlation coefficients statistically (p<0.05). Accordingly, these values also change when it titrates. But it is weakened weights as a measure of relationship.
Conclusion: Although fever comes to mind first in Brucellosis, it was observed that the first complaint of individuals in our study was complicated surgery, and fever ranked third. For this reason, Brucellosis should be approached with suspicion, since it is endemic in individuals presenting with non-specific complaints. It is widely present between serum titer and ESR, and C-reactive protein as markers of inflammation. In individuals with high vibration and inflammation markers, controlled caution should be exercised. Even treatment times can be changed.


1. Altay G. K&uuml;lt&uuml;r Pozitif 70 Bruselloz hastasının klinik velaboratuvar verilerinin değerlendirilmesi &amp; antibiyotikduyarlılıklarının E-test y&ouml;ntemi ile incelenmesi, UzmanlıkTezi. Sağlık Bakanlığı Haseki Eğitim ve Araştırma HastanesiEnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı,İstanbul, 2008.
2. Shapiro DS, Wong JD. Brucella. Murrey PR, Baron EP, Faller MA,Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7.Edition. American Society for Microbiology: 1999: 625-629.
3. &Ccedil;i&ccedil;ek Y. Bruselloz tanılı hastaların klinik, laboratuvar veepidemiyolojik &ouml;zelliklerinin incelenmesi. 2021. file:///C:/Users/admn/Downloads/bruselloz-tanili-hastalarin-klinik-laboratuvar-ve-epidemiyolo jik-ozelliklerinin-incelenmesi.pdf
4. Bilgehan H. Klinik Mikrobiyolojik Tanı. Fak&uuml;lteler Kitabevi,Barış Yayınları; İzmir. 1992: 203-207.
5. Bilgehan H. Brucella. Klinik Mikrobiyoloji-&Ouml;zel Bakteriyolojive Bakteri Enfeksiyonları. 10.baskı. Barış Yayınları, Fak&uuml;ltelerKitabevi; İzmir. 2004: 157-168.
6. Dabanlıoğlu B. Erzincan ili ve y&ouml;resinde bruselloz seroprevalansıve seropozitif olguların klinik bulgularla ilişkisi. Doktora Tezi,Erciyes &Uuml;niversitesi Sağlık Bilimleri Enstit&uuml;s&uuml;, Kayseri, 2005.
7. Ulug M, Can-Ulug N. Brusellozlu 78 olgunun degerlendirilmesi/evaluation of 78 cases with brucellosis. Klimik Derg.2010;23(3):89.
8. Aydın FE. S&uuml;t ve s&uuml;t &uuml;r&uuml;nlerinde Brucella cinsi bakterilerinaraştırılması, Y&uuml;ksek Lisans Tezi, Mersin &Uuml;niversitesi SağlıkBilimleri Enstit&uuml;s&uuml; Tıbbi Mikrobiyoloji Anabilim Dalı, Mersin,2007.
9. Sel&ccedil;uk K. Bruselloz ve tedavi sorunu. İnfeksiyon Derg (Turk JInfect). 2006;20(3):227-230.
10. Rubinstein E, Lang R, Shasha B, et al. Invitro susceptibility ofBrucella melitensis to antibiotics. Antimicrob Agents Chemother.1991;35(9):1925-1927.
11. Akpınar O. Historical perspective of brucellosis: a microbiologicaland epidemiological overview. Le Infezioni in Medicina.2016;24(1):77-86.
12. Top&ccedil;u AV, S&ouml;yletir G, Doğanay M, S&ouml;zen TH. Bruselloz. In:İnfeksiyon Hastalıkları. Nobel Ankara, Tıp Kitabevi: 1996: 476-491.
13. T&uuml;rk&ccedil;apar N, Kurt H. Bruselloz. In: Kurt H, G&uuml;ndeş S, Geyik MF,eds. Enfeksiyon Hastalıkları. Nobel Tıp Kitabevi: 2004: 7: 54-61.
14. B&uuml;ke &Ccedil;, &Ccedil;i&ccedil;eklioğlu M, T&uuml;rk M, Atalay S, Tuncel M. Ovakentbeldesinde bruselloz seroprevalansı ile hastalık konusundakibilgi ve davranışın saptanması. İnfeksiyon Derg. 2006;20(1):23-26.
15. K&ouml;se Ş, Senger SS, Akko&ccedil;lu G, et al. Clinical manifestations,complications, and treatment of brucellosis: evaluation of 72cases. Turk J Med Sci. 2014;44(2):220-223. doi:10.3906/sag-1112-34
16. Tohme A, Zein E, El Rassi B, Koussa S, Nasnas R. Humanbrucellosis in Lebanon. clinical features and therapeuticresponses in 88 patients. J Med Liban. 2004;52(3):149-155.
17. Sa&ccedil;ar S, Hır&ccedil;ın-Cenger D, Toprak S, Demir M, Turgut, H.Otuz bruselloz olgusunun klinik değerlendirilmesi.İnfekiyonDerg.2008;22(1):11-14.
18. Arapovic J, &Scaron;picic S, Ostojic M, et al. Epidemiological, clinicaland molecular characterization of human brucellosis in Bosniaand Herzegovina-an ongoing brucellosis outbreak. Acta MedicaAcademica. 2018;47(1):50-60.
19. Şahin M, Cesur S, Enki S. Endemik olduğu bir b&ouml;lgeden 83 olguile brusella enfeksiyonu. Ortadoğu Tıp Derg. 2019;11(2):101-106.
20. Demir T. Seroprevalence of brusellosis in Kırşehir province andsignificance of serological and biochemical tests in the diagnosisof brucellosis.Sel&ccedil;uk Med J. 2012;28(3):173-177.
21. Kalkan A, Felek S, Akbulut A, Papila &Ccedil;, Demirağ K, Kılı&ccedil; SS.Bruselloz i&ccedil;in risk taşıyan kişilerde mesleklerinde &ccedil;alışmas&uuml;resinin bruselloz seropozitifliği ve agl&uuml;tinasyon titresi &uuml;zerineetkisi.Flora. 1998;3(2):107-112.
22. Yardımcı C, Sarı ND, Ceylan B, Ulut&uuml;rk R, Fincancı M.Brusellozlu olgularda semptomların s&uuml;resi ile standart t&uuml;pagl&uuml;tinasyon titreleri, kan k&uuml;lt&uuml;rlerinde &uuml;reme ve lokomotorsistem tutulumu arası ilişkinin irdelenmesi. G&ouml;ztepe Tıp Derg.2009;24(2):69-72.
23. Kazak E, Akalın H, Yılmaz E, et al. Brucellosis: a retrospectiveevaluation of 164 cases. Singapore Med J. 2016;57(11):624-629.doi:10.11622/smedj.2015163
24. Shi C, Wang L, Lv D, et al. Epidemiological, clinical andlaboratory characteristics of patients with Brucella infection inAnhui province, China. Infect Drug Resist. 2021;14:2741-2752.doi:10. 2147/IDR.S319595
25. Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment ofbrucella spondylitis: lessons from an impossible meta-analysesand initial report of efficacy of a fluoroquinolone-containingregimen. Int J Antimicrob Agents. 2004;24(5): 502-507.
26. Kizilkilic O, Turunc T, Yildirim T, Demiroglu YZ, Hurcan C,Uncu H. Successful medical treatment of intracranial abscesscaused by Brucella spp. J Infect 2005;51(1):77-80.
27. Kaya S. Bruselloz ve tedavi sorunu.İnfeksiyon Derg (Turk J Infect).2006;20(3):227-230.
28. Montejo JM, Alberola I, Glez-Zarate P, et al. Open, randomizedtherapeutic trial of six antimicrobial regimens in the treatment ofhuman brucellosis. Clin Infect Dis. 1993;16(5):671-676.
29. Yavuz SŞ, Xu C, Benli A, et al. The Turkish clinical microbiologyand infectious diseases society (KLİMİK) evidence-basedguideline for the diagnosis and treatment of Brucellosis,2023.Klimik Derg. 2003;36(2):86-123.
Volume 2, Issue 3, 2023
Page : 89-94
_Footer